Platelet alpha IIb beta 3: a pharmacological integrin as a target to design new molecules with antithrombotic activity.
Marguerie
G
G
Département de Biologie Moléculaire et Structurale, INSERM U 217, Grenoble, France.
Jarrin
A
A
Andrieux
A
A
D000595:Amino Acid Sequence; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D001792:Blood Platelets / Q000378:metabolism*; D019483:Disintegrins; D015195:Drug Design; D006801:Humans; D016023:Integrins / Q000037:antagonists & inhibitors*; D008969:Molecular Sequence Data; D009842:Oligopeptides / Q000494:pharmacology; D010455:Peptides / Q000494:pharmacology; D010975:Platelet Aggregation Inhibitors / Q000138:chemical synthesis / Q000494:pharmacology*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D014688:Venoms / Q000494:pharmacology; D014757:Viper Venoms / Q000494:pharmacology
D000911:Antibodies, Monoclonal; D019483:Disintegrins; D016023:Integrins; D009842:Oligopeptides; D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D014688:Venoms; D014757:Viper Venoms; C047981:arginyl-glycyl-aspartic acid